Gender Incongruence: Puberty Suppressing Hormones

Tim Roca Excerpts

Wednesday 30th April 2025 Westminster Hall

[Tim Roca (Macclesfield) (Lab)]

It is a pleasure to serve under your chairship, Ms Lewell. I wanted to speak today because, as has already been said, this is a really important debate—one that must be had in a respectful and open manner. I am particularly grateful to the hon. Member for Reigate (Rebecca Paul) for opening the debate in precisely that way.

There needs to be a space to debate these topics openly and to engage with each other constructively because ultimately this issue is about the safety and wellbeing of young people. These are some of the most vulnerable, and often frightened, people in our schools and medical settings. They deserve a debate based on fact, open to new ideas and evidence, and respectful of their choices and identities.

The Cass review—an important review—did not find that puberty blockers cause harm in young people. Dr Cass made it clear that puberty blockers could, in the right circumstances, be effective and valuable in helping young people. That is absolutely why we need a rigorous, safe and scientific trial to determine, once and for all, the efficacy of puberty blockers in treating gender dysphoria.

I am grateful that the review also made clear that gender dysphoria is a diagnosable, recognisable and treatable condition. It is not about boys and girls being confused, nor is it caused by the media or by playing with the “wrong” toys; it is something that has been studied, proven and diagnosed. Ultimately, we are also talking about the trans community, which I think we all agree deserves dignity and respect.

I have to say that I am not a scientist, doctor or expert, and I expect that many other hon. Members are not either. It is therefore incumbent on us all to listen to experts of all kinds who have welcomed the call for a substantial clinical trial into puberty blockers. That would not be the first trial, as many in the UK and internationally have found favourable evidence. However, I will never not be in favour of more evidence and in particular of a rigorous UK trial.

An outcome of the review was that a trial into the use of puberty blockers for those with gender dysphoria was welcomed, as I say, and that that trial

“should be part of a programme of research which also evaluates outcomes of psychosocial interventions and masculinising/feminising hormones.”

I am proud that the Government support a holistic approach to the treatment of gender dysphoria, with proper psychological and physical support as well as treatment. I urge all hon. Members to listen to that call for more evidence. The Cass review made that point strongly and expressed regret that a controlled study was not delivered in 2011, specifying:

“There are many reports that puberty blockers are beneficial in reducing mental distress and improving the wellbeing of children and young people with gender dysphoria”.

It went on to say:

“Importantly some children within this group who remain gender incongruent into puberty may benefit from puberty blockers and will be able to enter the specialist component of the service and access the puberty blocker trial in a timely way”.

The review did not rule puberty blockers out of hand completely, but wanted to ensure that there was a decent evidence base, because ultimately we are talking about young people. As we debate this issue, we should agree that more facts and evidence help, whereas conjecture, opinion and speculation only muddy the waters. I am very keen to see the framework for the trial as soon as possible—I think the hon. Member for Reigate makes some good points—so that we see the results as quickly as possible in a safe way. If they demonstrate that puberty blockers are beneficial for young people with gender incongruence, I hope all those who claim to want to protect and support young people accept that fact.